pharma · Sickle Cell Disease
THERAVIA
theravia drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
theravia drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L01) compound in theravia's portfolio. Molecular target: Ribonucleoside-diphosphate reductase RR1.
US regulatory status: approved. Molecular target: Ribonucleoside-diphosphate reductase RR1.
Development asset linked to theravia in public FDA and regional records.
Development asset linked to theravia in public FDA and regional records.